361 Capital’s Intellia Therapeutics NTLA Stock Holding History

361 Capital’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-94,772	Closed	-$1.39M	–	358
2019 Q4	$1.39M	Buy	+94,772	New	+$1.32M	0.38%	90
2018 Q4	–	Sell	-64,299	Closed	-$1.84M	–	376
2018 Q3	$1.84M	Buy	+64,299	New	+$1.87M	0.4%	91

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AVAI

Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return

Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

361 Capital's NTLA Position: Q1 2020 in Review

361 Capital sold out of Intellia Therapeutics (NTLA) in Q1 2020, closing a stake of 94,772 shares — an estimated $1.39M sold.

361 Capital first reported a position in NTLA in Q3 2018 and held it in 2 quarters. The position peaked at $1.84M in Q3 2018. 140 funds tracked by Wall St. Rank hold NTLA as of Q1 2020.

361 Capital reported no remaining Intellia Therapeutics position as of Q1 2020 after selling out during the quarter.
361 Capital sold 94,772 Intellia Therapeutics shares in Q1 2020, an estimated $1.39M.
361 Capital first reported a position in Intellia Therapeutics in Q3 2018 and held it in 2 quarters.
361 Capital's Intellia Therapeutics position peaked at $1.84M in Q3 2018.
140 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2020.

Based on 361 Capital's 13F filing for Q1 2020, filed 13 May 2020.